With reference to the report published, the global stem cells market size was projected at USD 9.6 billion in 2019. It is expected to grow by 8.2% CAGR during the period of the forecast.
In spite of being contentious, these stem cells have increased considerable awareness from the multidisciplinary society of scientists. The substantial growth in stem cell sourced investigation and the massive accomplishment of the regenerative medication are anticipated to power the enlargement of the market for stem cells.
Mechanization in the cord blood, as well as adult stem cell processing along with the storage space, are the input technologies estimated to power the expansion of the market for adult cord blood stem cells. Moreover, important companies operating in this market, are concerned with research cooperation to reprogram baby stem cells from umbilical cord blood, in addition to umbilical cord tissue into iPSCs.
This expertise has achieved importance, during the previous years, since it is precisely connected to the healing of injured tissues, unhealthy organs, as well as regenerative medication. Research actions targeted to improve polymeric biomaterial methods and have observed a growth in current years. These systems perform as a niche that helps the endurance of stem cells.
Greater occurrences of the diseases have made possible the improvement of the vaccines by means of the diverse human being diploid with non-tumorigenic cell lines. Growth in demand and alertness, in addition to continuing R&D for the improvement of the vaccines in contradiction of a variety of diseases, are the factors anticipated to power the expansion of the stem cells market, throughout the period of the forecast.
A number of cell lines sourced influenza vaccines, for example, PER.C6 origin vaccines by Crucell, the technology of Vero cell line by Baxter, and Madin-Darby Canine Kidney (MDCK) by Solvay, are getting produced. These are active in compelling demand for these products for vaccine making. Besides, increasing demand for regenerative medication is, moreover estimated to boost the expansion of the market.
The innovators of the Biopharmaceuticals are at the front position of the individual reaction to the coronavirus pandemic. Large numbers of foremost biotech firms are in the center of competition, to explore the Sars-Cov-2 genome as well as make ready a practicable vaccine for the same. In contrast to the rapidity of the reaction to SARS/MERs and so forth, the biotech units are exploring SARs-Cov-2 at an unmatched speed and a substantial quantity of finances is being deposited in the R&D actions. By means of the numerous candidates involved in an experiment, the private, as well as public sectors, are expected to perform in unity, for the projected phase, in anticipation of a vaccine is developed for Covid-19.
In 2019, allogenic therapy retained the major share of revenue and is estimated to sustain its supremacy, all the way through the estimated period. Allogenic cells possess a benefit since they generate their individual resistant stem cell that kills the cancer cells, which stay behind even later the high dosage action with cytotoxin drugs. This reaction is described as a graft-versus-cancer result and is utilized in the action, otherwise prevention of cancer degeneration.
As an essential stage, the technology of cell acquisition is expected to make up the biggest share and is likely to uphold this place, during the period of the forecast. Increasing alertness regarding the importance of stem cells has produced considerable development in cell harvesting. Sequentially, this has contributed to its anticipated bigger share.
Due to the presentation of new reagents along with kits, that are convenient for optimizing the manufacture of stem cells, cell production is expected to observe significant enlargement during the near future. It comprises sophisticated modern technology for the quantization of stem cells and the integration of developments via multi-cellular treatment.
Regenerative medicine held the leading share of the stem cells market in 2019, due to increasing acceptance and continuing progress of companion diagnostics along with custom-made medication designed for the treatment in oncology and additional persistent diseases. Regular investigation for the usage of these stem cells, meant for the induction of innovative technologies to, eliminate the tumor and improve methodologies for the transplantation, are moreover, expected to increase the enlargement of the market, during the period of the forecast.
In 2019, the sector of adult stem cells was the frequently utilized product and is estimated to carry on its domination on the stem cells market, during the study period. This is credited to the compatibility with the individual body, the negligible necessity of manual labor for the production, and a very small risk of infectivity linked with sub-culturing.
Due to its capability to considerably move forward the development of the medicine in addition to the clinical research, the iPS sector is estimated to observe the highest progress, during the period of the forecast. The capability of iPS cells to connect possessions of disease with the structure of definite stem cells to investigate the hereditary connection amid patients and the diseases, intended for the invention of the drug, is estimated to positively impact the enlargement of this sector.
Europe is recognized for its excellent quality of research, later China. Due to the dedicated products in the cell-sourced treatment and a hefty populace of patients, the Asia Pacific area is likely to develop at a profitable speed. In the domain of iPS research, Japan was the pioneer. A Japan headquartered pharmaceutical company, HEALIOS K.K., is one of the earliest companies to experiment with the iPS-sourced treatment, within the nation. The company anticipates the commercialization of its manufactured goods, before 2022. Such kinds of proposals are estimated to increase revenue creation, within the region.
As a result of greater investment in R&D for cytological research, North America held the major share in the stem cells market, in 2019. Rising acceptance of stem cell treatment in the market, solid arrangements for compensation along highly developed healthcare infrastructure are the factors, responsible for the domination of the market, within this region. Due to the existence of the most important biotechnology companies, wide-ranging funding by the government, and growing research activities, within the region, the U.S. is the most important nation-state in research, rather than other nations.
The key companies are concentrating on the extension of their contributions, by way of wide-ranging R&D plus the construction of associations, as well as the partnerships, with other foremost companies, to maintain their position in the market. For example, Evotec SE extended its association with Celgene, in June 2019, to take in a novel iPSC, targeted in favor of finding out the disease transforming treatments, used for the patients affected by neurodegenerative sickness.
Some of the companies for stem cells market are:
• Advanced Cell Technology Inc
• Human Longevity Inc
• BIOTIME, INC.
• Celgene Corporation
• Promethera Biosciences
• Cytori Therapeutics
• Osiris Therapeutics Inc.
• STEMCELL Technologies Inc.
The base year for estimation
Actual estimates/Historical data
2016 - 2018
2020 - 2027
Revenue in USD Million and CAGR from 2020 to 2027
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
U.S., Canada, Germany, U.K., China, Japan, Brazil, South Africa
Revenue forecast, company share, competitive landscape, growth factors, and trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of the customization
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2027. For the purpose of this study, Million Insight's has segmented the global stem cells market report on the basis of product, application, technology, therapy, and region:
• Product Outlook (Revenue, USD Million, 2016 - 2027)
• Adult Stem Cells (ASCs)
• Neuronal ASCs
• Hematopoietic ASCs
• Mesenchymal ASCs
• Umbilical Cord ASCs
• Dental ASCs
• Adipose‐derived ASCs
• Dedifferentiated fat (DFAT) Cells
• Other ASCs
• Human Embryonic Stem Cells
• Induced Pluripotent Stem Cells
• Very Small Embryonic Like Stem Cells
• Application Outlook (Revenue, USD Million, 2016 - 2027)
• Regenerative Medicine
• Cardiovascular and Myocardial Infraction
• Liver Disorder
• Drug Discovery and Development
• Technology Outlook (Revenue, USD Million, 2016 - 2027)
• Cell Acquisition
• Bone Marrow Harvest
• Umbilical Blood Cord
• Cell Production
• Therapeutic Cloning
• In-vitro Fertilization
• Cell Culture
• Expansion and Sub-Culture
• Therapy Outlook (Revenue, USD Million, 2016 - 2027)
• Regional Outlook (Revenue, USD Million, 2016 - 2027)
• North America
• The U.S.
• The UK
• The Asia Pacific
• Latin America
• Middle East & Africa
• South Africa
Research Support Specialist, USA